IceCure Medical Ltd. (ICCM)
NASDAQ (CM) NASDAQ (CM) Primary 
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07.
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07.
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
IceCure Medical Ltd. ICCM recently announced the publication of data from an independent study evaluating its ProSense cryoablation system in the peer-reviewed journal — Cancers.
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with CryoProbes.
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade
IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
IceCure Medical Ltd (ICCM) Q1 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2024 Earnings Conference Call May 28, 2024 11:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer Tlalit Bussi Tel-Tzure - VP, Business Development & Global Marketing Ronen Tsimerman - Chief Financial Officer & Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Anthony Vendetti - Maxim Group Ben Haynor - Lake Street Capital Markets Yi Chen - H.C. Wainwright Operator Good morning, and thank you for standing by.
